TipRanks

Notifications

Tag: CARA

Total 148 Posts

Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Cara Therapeutics (CARA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELCResearch Report) and Cara Therapeutics (CARAResearch Report) with bullish sentiments.

Celcuity (CELC)

In a report released today, Gil Blum from Needham maintained a Buy rating on Celcuity, with a price target of $24.00. The company’s shares closed last Wednesday at $18.16, close to its 52-week high of $18.95.

According to TipRanks.com, Blum is a 4-star analyst with an average return of 7.9% and a 46.6% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Recursion Pharmaceuticals, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Celcuity is a Strong Buy with an average price target of $32.00.

See the top stocks recommended by analysts >>

Cara Therapeutics (CARA)

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Cara Therapeutics, with a price target of $5.00. The company’s shares closed last Wednesday at $0.87, close to its 52-week low of $0.50.

According to TipRanks.com, Stringer is a 3-star analyst with an average return of 3.5% and a 42.3% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Apellis Pharmaceuticals, and Lexicon Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cara Therapeutics with a $7.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CELC: